Therefore, we aimed to employ in-depth metabolomics technologies to study the metabolomic profiles of a cohort of patients with DOCK8 deficiency and severe AD to explore biomarkers that potentially reflect disease pathogenesis and may contribute towards improved disease monitoring, and ultimately novel clinical interventions. Here, DOCK8 is linked to Alzheimer disease.